)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Fredun Pharmaceuticals
Fredun Pharmaceuticals (539730) investor relations material
Fredun Pharmaceuticals Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 26/27 earnings summary13 Aug, 2026
Executive summary
Standalone total income for Q1 FY 2027 reached INR 228.25 crores, up 90.44% year-over-year, with EBITDA at INR 32.78 crores, up 92.90% year-over-year, and net profit at INR 13.17 crores, up 94.63% year-over-year.
Unaudited financial results for the quarter ended 30 June 2026 were reviewed and approved by the Board on 5 August 2026.
Both standalone and consolidated results were prepared in accordance with Ind AS and reviewed by statutory auditors with unmodified conclusions.
Financial highlights
Q1 FY 2027 standalone total income: INR 228.25 crores (+90.44% YoY); EBITDA: INR 32.78 crores (+92.90% YoY); net profit: INR 13.17 crores (+94.63% YoY).
Standalone revenue from operations for the quarter was ₹22,775.55 lakhs, up from ₹11,940.29 lakhs year-over-year.
Standalone net profit for the quarter was ₹1,316.81 lakhs, compared to ₹676.58 lakhs in the same quarter last year.
Basic EPS for the quarter was ₹23.89, up from ₹14.33 year-over-year.
EBIT margin improved to 9%-10% in Q1, with expectations to reach 12%-13% over the next 12 quarters.
Outlook and guidance
Blended revenue growth of 30%-35% expected for the next three years, driven by both new and vintage brands, capacity expansion, and product portfolio additions.
Pet Care and Gx businesses expected to grow 30%-50% annually for the next three to five years, with significant market potential due to low pharma penetration.
Revenue target for FY 2027 is around INR 800 crores, with the company on track to overachieve.
Results were reviewed and recommended by the Audit Committee and approved by the Board, indicating continued compliance and operational stability.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Fredun Pharmaceuticals
- FY00 losses persisted as export disruption prompted a shift to direct markets and new products.539730
Q4 99/00 - Profit returned, but Rs 28.48 lakh of audit adjustments and debt risks clouded the outlook.539730Q4 00/01
- Turnover surged, but a deferred-tax charge and disputed excise refund clouded earnings.539730Q4 01/02
- Exports expanded as FY net profit reached ₹2.72 lakh despite accumulated losses.539730Q4 02/03
- Turnover grew 32% and the year returned to profit, despite significant audit qualifications.539730Q4 04/05
- Higher FY04 sales could not offset liquidity pressure and a Rs 14.11 lakh net loss.539730Q4 03/04
- Turnover plunged as beta-lactam production stopped and SEZ competition intensified.539730Q4 05/06
- Higher sales and profit, backed by export orders, alongside an AS 28 audit issue.539730Q4 06/07
- Higher sales and PAT, with export orders buoying the outlook despite audit and excise risks.539730Q4 07/08
- Lower revenue, weaker net profit, and export orders underpin a cautiously promising outlook.539730Q4 08/09
Next Fredun Pharmaceuticals earnings date
Q2 26/2710 Nov, 2026
Fredun Pharmaceuticals
Next Fredun Pharmaceuticals earnings date
Q2 26/2710 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Fredun Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing and export of a wide range of medicinal products. The company produces formulations including tablets, capsules, powders, and liquid orals across various therapeutic categories. It operates as a contract manufacturer for global pharmaceutical brands and also markets its own branded generics. Fredun Pharmaceuticals Limited serves both domestic and international markets, complying with regulatory standards in multiple regions. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.